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Edited by Robert BaroukiAbstract New Zealand obese (NZO/HlLt) male mice develop
polygenic diabetes and altered phosphatidylcholine metabolism.
The gene encoding phosphatidylcholine transfer protein (PC-
TP) is sited within the support interval for Nidd3, a recessive
NZO-derived locus on Chromosome 11 identiﬁed by prior segre-
gation analysis between NZO/HlLt and NON/Lt. Sequence
analysis revealed that the NZO-derived PC-TP contained a
non-synonymous point mutation that resulted in an Arg120His
substitution, which was shared by the related NZB/BlNJ and
NZW/LacJ mouse strains. Consistent with the structure-based
predictions, functional studies demonstrated that Arg120His
PC-TP was inactive, suggesting that this mutation contributes
to the deﬁciencies in phosphatidylcholine metabolism observed
in NZO mice.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The New Zealand obese (NZO) mouse strain is character-
ized by juvenile-onset obesity and maturity-onset hyperinsuli-
nemia, hyperleptinemia, hyperglycemia, and hypertension.
Approximately 50% of NZO males develop obesity-associated
diabetes, or diabesity. Nonobese nondiabetic (NON) is an
unrelated mouse strain that spontaneously develops impaired
glucose tolerance associated with defective insulin secretion
by pancreatic beta cells. In contrast to NZO, male NON mice
do not progress from impaired glucose tolerance to hypergly-
cemia when maintained on standard diets. When NON and
NZO are intercrossed, quantitative trait loci (QTL) derived
from both strains produce (NZOxNON)F1 male mice ofAbbreviations: MLV, multilamellar vesicle; NON, nonobese nondia-
betic; NZO, New Zealand obese; PC, phosphatidylcholine; PC-TP, PC
transfer protein; PEMT, phosphatidylethanolamine n-methyl transfer-
ase; PS, phosphatidylserine; QTL, quantitative trait locus; SUV, small
unilamellar vesicle
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doi:10.1016/j.febslet.2006.09.066equivalent obesity to NZO parentals, but the frequency of
males developing diabesity is increased to 90–100% [1,2].
In a eﬀort to identify the genetic diﬀerences that underlie the
tendency of NZO mice to develop diabesity, we recently
showed that hepatic activities of two key enzymes of phospha-
tidylcholine (PC) metabolism, phosphatidylethanolamine n-
methyl transferase (PEMT) and choline kinase were lower in
(NZOxNON)F1 males than in either parental strain [3,4].
The Pemt gene encoding PEMT is sited on Chromosome 11
within the support interval for the more proximal of two link-
age peaks designated as Nidd3, an NZO-derived QTL control-
ling serum insulin concentrations [1]. We tested the hypothesis
that an additional NZO-derived gene contributing to the unex-
pected reduction in PC metabolism in the metabolic milieu of
the F1 mice might reside in the support interval for the more
distal linkage peak comprising Nidd3. Indeed, this region
was found to contain Pctp, the gene encoding phosphatidyl-
choline transfer protein (PC-TP). PC-TP is a highly speciﬁc
25 kDa PC binding protein that is enriched in cytosol of hepa-
tocytes [5,6] and regulates lipid metabolism in the liver [7–9]. In
the present report, we show that the NZO genome carries a
functionally null Pctp allele, which was present only in two
other closely related New Zealand mouse strains.2. Materials and methods
2.1. Materials
Restriction endonucleases, as well as all other routine molecular re-
agents were purchased from either Roche Applied Science (Indianap-
olis, IN) or Invitrogen (Carlsbad, CA). Egg yolk PC, brain
phosphatidylserine (PS) and bovine heart cardiolipin were from Avanti
Polar Lipids (Alabaster, AL). L-a-1-Palmitoyl-2-linoleoyl-[linoleoyl-
1-14C] PC (50 mCi/mmol) was from NEN Life Science Products (Bos-
ton, MA) and [1a,a(n)-3H] and cholesteryl oleate (44 Ci/mmol) was
from Amersham Biosciences (GE Healthcare Bio-Sciences Corp., Pis-
cataway, NJ).
2.2. Mice
Mice were maintained on a chow diet containing 6% fat at The Jack-
son Laboratory (Bar Harbor, ME) in temperature and humidity con-
trolled rooms with 14/10-h light–dark cycles. At 8 weeks of age, mice
were euthanized by CO2 asphyxiation. Livers were harvested immedi-
ately and then snap frozen and stored at 80 C. Genomic DNA sam-
ples from individual mouse strains listed in Table 1 were obtained from
the DNA Resource of The Jackson Laboratory. All protocols were ap-
proved by the institutions’ Animal Care and Use Committees.blished by Elsevier B.V. All rights reserved.
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Hepatic mRNA expression of PC-TP was determined by quantita-
tive real-time PCR. Total liver RNA was isolated for preparation of
cDNA by standard techniques. Pctp-speciﬁc PCR primer sequences
were 5 0-ATAACCATCTACCGGCTGCT-30 (forward) and 5 0-
CAAGGTTGCTTGGGAATGAG-30 (reverse). Quantitative real-
time PCR was performed on a LightCycler (Roche Applied Science)
using SYBR green for DNA detection and cyclophilin RNA for nor-
malization.Fig. 1. Localization of Pctp within the Nidd3 locus. The Pctp gene
maps within a previously published QTL peak for Nidd3 aﬀecting both
serum insulin and body weight [1]. The diabetogenic contribution was
from NZO.2.4. Western blot analysis PC-TP
Protein expression in liver homogenates was determined by Western
blot analysis using three diﬀerent polyclonal antibodies: (1) to the C-
terminus of PC-TP (aa 200–214) [10], (2) to an internal peptide (aa
50–63) [11] and (3) to puriﬁed recombinant wild type PC-TP [11]. Blots
were stripped and reprobed with a MAP/ERK kinase 1 antibody
(catalog number PRB-260C, Covance, Richmond, CA) to control for
diﬀerences in protein loading. Detection was by enhanced chemilumi-
nescence.
2.5. Nucleotide sequence analysis and predicted protein structures
The exons and 5 0-ﬂanking region of Pctp were ampliﬁed using PCR
primers designed to the nucleotide sequence of the C57BL/6J strain
(http://www.ensembl.org/Mus_musculus) and then subjected to nucleo-
tide sequencing in both forward and reverse directions. Multiple
nucleotide and amino acid sequence alignments were performed using
CLUSTALW and visualized with Jalview [12,13]. The crystal structure
of PC-TP in complex with di-linoleoyl-phosphatidylcholine (Protein
Data Bank entry 1LN1) was modeled as the Arg120His mutant using
O [14], which was also used to measure interatomic distances. The side
chain dihedral angles near side chain rotamer values (v1 = 176) were
modeled by inspection and produced no unacceptably close contacts
to the remainder of the protein or ligand.
2.6. In vitro activity of wild type and mutated PC-TPs
A QuickChange Site-Directed Mutagenesis kit (Stratagene Cloning
Systems, La Jolla, CA) was used to modify a synthetic human PC-
TP cDNA that was cloned into pET11a (Novagen, EMD Biosciences,
San Diego, CA) [11] so that it instead encoded Arg120His PC-TP.
Mutagenesis was conﬁrmed by nucleotide sequencing. Wild type and
Arg120His in pET11a, as well as pET11a vector alone were trans-
formed into E. coli BL21(DE3). Activities of native and recombinant
expressed proteins were determined in cytosolic preparations from
mouse livers and E. coli, respectively. Brieﬂy, PC transfer activity
was determined by measurement of intermembrane transfer of radio-
labeled phospholipids [15]. Donor small unilamellar vesicles (SUVs)
were prepared by bath sonication of PC, 14C-PC, 3H-cholesteryl oleate
dispersed in 5 mM EDTA and 50 mM Tris at pH 7.2. Multilamellar
vesicles (MLVs) consisting of PC and cardiolipin (95:5 mol%) in the
same buﬀer were prepared by rotary shaking. Solutions containing
PC-TP were incubated together in a 37 C shaking water bath with do-
nor SUVs (50 ll), acceptor MLVs (100 ll) adjusted to a ﬁnal volume of
500 ll with buﬀer. Control samples contained no added protein. Fol-
lowing 30 min of incubation, MLVs were pelleted by centrifugation
and the [14C] PC and [3H] cholesteryl oleate contents in a 350 ll aliquot
of SUVs that remained in suspension were determined by liquid scin-
tillation counting. Because cholesteryl oleate is not transferred by PC-
TP, 3H concentrations were employed to correct for small losses of
SUVs during centrifugation. In this manner, [14C]-PC transferred from
SUVs to MLVs was reﬂected by decreases in the 14C/3H ratio of SUVs.
Speciﬁc activities were estimated by normalizing activities to cytosolic
expression levels, which were quantiﬁed by densitometric analysis of
Western blots [16].
2.7. Membrane binding of wild type and mutated – PC-TPs
Binding of wild type and Arg120His PC-TP to SUVs was measured
as previously described [11]. To produce wild type and mutated PC-
TPs in the form of His-tag fusion proteins, we cloned cDNAs encoding
wild type and Arg120His into pET19b (Novagen). His-tag proteins
were puriﬁed from soluble bacterial proteins [11] and dialyzed against
10 mM Tris–HCl, 20 mM NaCl, 1 mM DTT and 1 mM NaN3 at 4 C.
Proteins were mixed together with SUVs (PC:PS molar ratio of 80:20)
to a ﬁnal volume 200 ll. The ﬁnal protein concentration (1.5 lM) was
held constant, whereas the SUV phospholipid concentration was var-ied to achieve phospholipid/protein molar ratios of 0–240. Mixtures
were incubated for 10 min at room temperature to allow binding of
proteins to SUV, and then unbound proteins were collected by ultra-
ﬁltration through Microcon YM100 100 kDa molecular weight cutoﬀ
ﬁlter (Millipore, Bedford, MA) by centrifugation at 3000 · g for
5 min. Unbound proteins remaining within the ﬁlter were eluted by
centrifugation (3000 · g for 2 min) of an addition 300 ll of buﬀer
and were combined with initial ultraﬁltrates. Ultraﬁltrates containing
unbound proteins were transferred to PVDF membranes (Immobi-
lon-P, Millipore) using a Bio-Dot SF Cell slot-blot apparatus (Bio-
Rad Laboratories, Hercules, CA) and probed with the antibody raised
to the C-terminus of PC-TP. Detection was by enhanced chemilumi-
nescence.3. Results
Fig. 1 presents a schematic diagram of the previously-re-
ported NZO-derived QTL for Nidd3 on Chromosome 11 [1]
that drew our attention to the possibility that the NZO Pctp
allele, because of its chromosomal position, might contribute
to the impaired PC metabolism. Indeed, as shown in Fig. 2,
multiple nucleotide sequence polymorphisms distinguished
the NZO Pctp allele from the other strains chosen for compar-
ative sequencing (NON/Lt, NOD/Lt, and C57BL/6J). Within
the gene promoter region 86 bp upstream from the transcrip-
tion initiation site, an A-to-G substitution within the CAAT-
box of the putative promoter [17] distinguishes NZO from
the other 3 unrelated strains sequenced. Between the CAAT
box and transcription initiation site in NZO mice, we also ob-
served that the 12 bp spanning between bp 80 to 69 were
deleted from the promoter region of Pctp. Two polymorphisms
were observed within the NZO coding region of Pctp. A syn-
Fig. 2. Sequence variations of Pctp in NZO compared with other mouse strains. In this schematic diagram of Pctp, the boxes represent exons. The
solid lines indicate the 5 0 promoter region and 3 0 ﬂanking DNA. The dashed lines indicate introns, which are not drawn to scale. Numeric values
indicate bp positions upstream (negative) or downstream (positive) with respect to the transcription initiation site (http://www.ensembl.org/
Mus_musculus). The positions of the ATG start codon, the TAA stop codon and AATAAA polyadenylation sequence are depicted as reference
points. Arrows indicate location and identity of sequence variations identiﬁed in NZO Pctp: There was an A–G substitution at bp 86 within in the
CCAAT-box of the promoter region and a deletion (represented by dashes) of 12 bp from 80 to 69. A C-to-T substitution at bp 338 within exon 3
was synonymous, leaving Ser at aa 110 unaltered. However, a G-to-A substitution at bp 367 in exon 4, was non-synonymous, resulting the
substitution of Arg at aa 120 with His. There were two additional sequence diﬀerences outside the coding region in exon 6, each of which consisted of
two bp insertions in NZO mice, as well as a 4 bp insertion and a 1 bp deletion in the NON strain.
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downstream from the transcription initiation site at bp 330
of the open reading frame) did not alter the identity of
Ser110. By contrast, a non-synonymous G-to-A substitution
was identiﬁed in exon 4 (367 bp downstream from the tran-
scription initiation site at bp 359 of the open reading frame).
This replaced Arg120 with His (i.e. Arg120His) in NZO mice.
In the 3 0-UTR, a series of 7 G bases beginning at bp 935 down-
stream of the transcription initiation site in C57BL/6J mice
was replaced with 9 G bases in NZO and 11 G bases in
NON. Beginning at bp 1492, the 15 bp sequence in C57BL/
6J was replaced by 17 G bases in NZO mice and 14 G bases
in NON mice. To gain additional insights into the temporal
origins of this substitution among mouse strains, we ampliﬁed
and sequenced exon 4 of Pctp from a variety of mouse
strains including the two closely-related NZB and NZW
strains (Table 1). The Arg120His substitution was present onlyTable 1
Comparison of Arg120His variant among 12 mouse strains
Mouse strain Nucleotide variant
on exon 4a
Amino acid variant
at residue 120
NZO/HILtJ A His
NZW/LacJ A His
NZB/BlNJ A His
NON/LtJ G Arg
EL/SuzSeyFrkJ G Arg
DDY/JclSidSeyFrkJ G Arg
NOD/LtJ G Arg
ALR/LtJ G Arg
ALS/LtJ G Arg
DBA/2J G Arg
C57BL/6J G Arg
TallyHo/Jng G Arg
aLocated 367 bp downstream from the transcription initiation site.in the Pctp alleles of the NZO-related NZB and NZW strains,
but not in a variety of other strains.
The ﬁnding of NZO polymorphisms in the gene promoter
and 3 0-UTR of Pctp suggested the possibility that mRNA
expression levels might be altered. However, quantitative
real-time PCR revealed that mRNA levels of Pctp in livers
of NZO mice were the same as in the NON and the F1 hybrid
(NZOXNON)F1 mouse strains. By Western blot analysis
using each of three diﬀerent anti-PC-TP antibodies, PC-TP
protein concentrations did not diﬀer in livers of NZO and
NON mice (data not shown). Expression levels were also the
same in (NZOxNON)F1 mice.
Fig. 3 illustrates the environment surrounding residue 120 in
the three dimensional structure of PC-TP [18]. The crystal
structure of PC-TP in its native form [16] reveals that
Arg120 interacts directly with the side chains of Asp70 and
Asp122. Asp70 is a member of helix a2 (residues 64–74), which
donates two additional residues to the PC binding site: Leu68,
which interacts with the sn-2 acyl chain of the bound PC mol-
ecule, and Tyr72, which also interacts with the sn-2 chain and
additionally interacts with the phosphoryl group of PC via its
side chain hydroxyl. Although mutation of Arg to His at posi-
tion 120 conserves the positive charge, the His side chain is
shorter than the native Arg residue and would not be expected
to interact with Asp70 in the same manner although it could
interact with Asp122 (imidazole NE2 atom to Asp 122 side
chain OD1 atom distance of 2.50 A˚). This altered interaction
of residue 120 with a2 would be predicted to aﬀect the confor-
mation or position of this helix and mediate altered interac-
tions of Leu68 and Tyr72 with the ligand, and perhaps alter
the activity of the protein as a result. Based upon this struc-
ture-based prediction, we evaluated the inﬂuence of the
Arg120His mutation on the activity of native and recombinant
PC-TP. We did not detect a diﬀerence in the PC transfer
Fig. 4. The Arg120His substitution inactivates PC-TP in vitro without
altering membrane binding. (A) PC-TP activities were compared
among vector, vector containing wild type or Arg120His PC-TP. The
indicated amounts of PC-TP in E. coli cytosol were used to measure
PC transfer activity in vitro. The assay of vector control consisted of
the corresponding amount of cytosolic protein. Data are represented
as means ± S.D. (B) Samples of cytosol containing wild type and
mutant PC-TP were admixed (50 lg total PC-TP) to achieve varied
molar ratios of wild type and Arg120His PC-TP. The nearly linear
increase in activity as a function of increasing proportion of wild type
PC-TP indicated that Arg120His did not inactivate the wild type
protein in vitro. (C) Membrane binding of His-tag wild type and
Arg120His PC-TPs was determined according to the free fraction of
protein as a function of increasing phospholipids/protein ratios. The
data are representative of duplicate determinations in two experiments.
Fig. 3. Predicted inﬂuence of the Arg120His substitution on PC-TP
structure. The three-dimensional structure of PC-TP (gray) in complex
with phosphatidylcholine (green). The interactions of Arg120 with
Asp70 and Asp122 are depicted by dotted lines, as are the interactions
of the phenolic hydroxyl group of Tyr72 with the ligand. A modeled
position of His120 (blue) is also depicted. Residues Leu68, Asp70 and
Tyr72 are donated from helix a2 (residues 64–74; pink). This helix may
mediate the eﬀects of the Arg120His mutation to the lipid binding
pocket.
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assay) from livers of NZO and NON mice. However, as shown
in Fig. 4A, robust PC transfer activity was observed for recom-
binant wild type protein, which increased in this assay in pro-
portion to the amount that was added, whereas minimal
activity was observed for the recombinant Arg120His mutant
protein, which did not diﬀer from the vector control.
Because genetic outcross between NZO and NON produces
an F1 male that is comparably obese, but develops diabesity at
a higher frequency than observed in NZO parental males [19],
we questioned whether the increased diabesity penetrance
might entail a further impairment of PC homeostasis via a
dominant-negative inactivation of the NON wild type
(Arg120) protein by the mutant NZO His120 PC-TP protein.
Using the in vitro assay, we admixed wild type and mutant
recombinant PC-TPs in varied molar ratios (Fig. 4B). We ob-
served an essentially linear increase in the activity of the wild
type PC-TP as its molar percentage in the mixture increased,
arguing against a dominant-negative eﬀect of the mutant pro-
tein.
Fig. 4C compares membrane binding of wild type and
Arg120His PC-TPs, as measured by the concentration of free
protein that passed through a ﬁlter that retained SUVs. As
the phospholipids/protein ratio was increased, reduced band
intensity was indicative of PC-TP binding to SUVs. These data
demonstrate that the Arg120His mutation did not reduce the
capacity of PC-TP bind to membranes.4. Discussion
The present study shows that the NZO/HlLtJ strain and its
two most closely related strains, NZB/BlNJ and NZW/LacJ all
share the same inactivating Arg120His mutation in their Pctp
allele. PC-TP is a member of the steroidogenic acute regulatory(StAR)-related transfer (START) domain-containing super-
family of proteins [20,21] and has also been designated StarD2
[22]. The gene encoding PC-TP is highly conserved among
mammals [6,17,23,24]. It is expressed in a number of human
[24] and mouse [23] tissues, but highest levels are generally
found in the liver. Experiments in tissue culture [25,26] and
in mice with homozygous disruption of Pctp [7–9] suggest a
role for PC-TP in hepatobiliary elimination of plasma choles-
terol.
Although we observed nucleotide sequence polymorphisms
in both the promoter region and the 3 0UTR of the NZO Pctp
gene, these did not inﬂuence hepatic mRNA expression levels.
Similarly there were no diﬀerences in PC-TP protein in livers of
NZO or NON mice, indicating that the Arg120His substitu-
tion did not alter protein stability. However, a notable obser-
vation in this study was that the Arg120His amino acid
H.-J. Pan et al. / FEBS Letters 580 (2006) 5953–5958 5957substitution inactivated recombinant expressed PC-TP in an
assay of intermembrane PC exchange. Although we did not
observe a diﬀerence in PC transfer activity between cytosolic
protein preparations from livers of NZO and NON mice, this
result most likely reﬂects the relative insensitivity of the in vitro
assay when PC-TP comprises a small fraction of the total pro-
tein in the assay, taken together with the contributions of other
soluble proteins in liver that exhibit PC transfer activity (e.g.
sterol carrier protein 2, StarD10 and phosphatidylinositol
transfer protein) [27]. It is also possible that another lipid
transfer protein may have compensated for the loss of PC-
TP activity in livers of NZO mice.
PC-TP binds PC non-covalently in a tight 1:1 stoichiometric
complex [5,16]. Its activity as a lipid transfer protein has been
well characterized using carefully standardized in vitro assays
[5]. To accomplish PC exchange, PC-TP must bind to a donor
membrane, release a PC molecule within its lipid-binding
pocket and then bind to a new one. Structural studies of PC-
TP [11,16] indicate that PC exchange at the membrane requires
a major conformational change in the protein. Once exchange
occurs, PC-TP must then desorb from the donor and bind to
an acceptor membrane, where a similar exchange of PC occurs.
A failure of any of these steps could have disrupted the activity
of recombinant PC-TP that was measured in the in vitro trans-
fer activity used in this study [28]. Arg in position 120 of
PC-TP is conserved among humans, cows, rats and mice [6],
supporting the likelihood that its conversion to His might lead
to signiﬁcant alterations in protein structure and function.
Based upon the predicted structure of Arg120His PC-TP, it
appears likely that the inability to transfer PC between mem-
branes results from altered binding of PC within the lipid-bind-
ing pocket of the protein. This possibility is supported by the
observation that the Arg120His substitution did not inﬂuence
membrane binding by PC-TP, which is mediated at least in
part by the C-terminal a-helix of the protein [11]. Although
the physiological signiﬁcance of inactivating PC-TP is not
known, these results are suggestive that the spontaneous muta-
tion of PC-TP adds to the additional defects in PC biosynthesis
elicited by reduced activities of PEMT and choline kinase in
the liver of NZO males [3].
The ﬁnding that only NZO, NZB, and NZW mice share the
Arg120His mutation indicates that the mutation had become
ﬁxed in the outbred progenitors maintained at the University
of Otago, New Zealand, prior to initiation of NZ inbred strain
development in 1948. The NZO and NZB strain had common
agouti progenitors and were separated at the third generation
of sib mating, at which point the latter strain was selected for
black coat color while selection for agouti coat and later, obes-
ity, was continued in the NZO line [29]. Although deriving
from the same outbred stock, the NZW strain was indepen-
dently selected for albino coat color from diﬀerent progenitors
than used to form the NZO and NZB lines [30].
In summary, nucleotide sequence analysis of Pctp revealed
diﬀerences between the NZO and NON alleles in both non-
coding and coding regions. One of the polymorphisms in the
coding region of the NZO allele resulted in an Arg120His sub-
stitution, a change that abrogated the in vitro activity of PC-
TP without inhibiting membrane binding. The ﬁnding of the
same Arg120His substitution in NZB and NZW Pctp shows
this mutation is not of recent origin. Admixture experiments
in vitro with cytosolic proteins from transformed E. coli pro-
ducing wild type or mutant PC-TP failed to show a dominantnegative eﬀect of the null allele product on wild-type activity.
Although the physiological signiﬁcance of inactivating PC-
TP is not known, the demonstration of a functionally null Pctp
allele in the NZO genome, coupled with reduced activities of
the PC biosynthetic PEMT and choline kinase enzymes [3] in
the liver of NZO males, further indicates signiﬁcant derange-
ments in lipid metabolism in this mouse model of polygenic
obesity and diabesity.
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